Helsinn closes financing agreement with BancaStato to support business objectives and growth New funding secured to expand the portfolio of late- and commercial-stage supportive care, oncology and...
Lugano, Switzerland, June, 12, 2023 - Helsinn Group (œHelsinn), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in...
Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs
Helsinn closes financing agreement with Oberland Capital
Helsinn announces the appointment of Dr Melanie Rolli as Group Chief Executive Officer
Lugano, Switzerland, October 18, 2022 - Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets, announces that research from an in vitro study of chlormethine gel has been published in the journal Dermatology and Therapy.
Last year, BridgeBio was riding high on back-to-back FDA approvals, including for cancer treatment Truseltiq. At the time, Helsinn Group wanted a piece of the pie and inked a deal worth up to $2.45 billion to split commercialization rights on the med.
Lugano, Switzerland, August 8, 2022 - Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets, announces its participation in the upcoming IASLC 2022 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer, taking place from 6-9 August in Vienna, Austria.
New data on Helsinn’s oncology pipeline presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2022 Lugano, Switzerland, June 02, 2022 - Helsinn Group (“Helsinn”), a fully...
Helsinn Establishes New R&D Hub in the U.S. to Support its Global Fully Integrated Targeted Therapy (FITT) Strategy New R&D hub will be based at U.S. subsidiary, Helsinn Therapeutics (U.S.),...